MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Exagen Interest Expense 2011-2026 | XGN
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Exagen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 2.34 M | 2.45 M | 2.62 M | 2.56 M | 3.49 M | 2.87 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.49 M | 2.34 M | 2.72 M |
Quarterly Interest Expense Exagen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 549 K | - | 557 K | 574 K | 638 K | - | 618 K | 606 K | 598 K | - | 678 K | 663 K | 645 K | - | 647 K | 635 K | 631 K | - | 909 K | 910 K | 901 K | - | 704 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 910 K | 549 K | 674 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 15.85 | -2.49 % | $ 171 M |  China |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Agilent Technologies
A
|
81 M | $ 115.06 | -0.29 % | $ 35 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
5.9 M | $ 1.13 | -2.59 % | $ 6.15 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 16.05 | -3.83 % | $ 855 M | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Interpace Biosciences
IDXG
|
-252 K | $ 2.3 | - | $ 10.2 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 23.13 | -1.28 % | $ 642 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 175.65 | 0.06 % | $ 8.71 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 493.53 | -1.59 % | $ 14.2 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 189.61 | -1.7 % | $ 135 B | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 120.93 | -2.22 % | $ 19.2 B | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.35 | -2.03 % | $ 403 M | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 14.43 | -3.93 % | $ 436 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 7.69 | -3.17 % | $ 985 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 78.6 | -9.83 % | $ 9.85 B | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.69 | -1.82 % | $ 87.3 K | USA |
 |
Biomerica
BMRA
|
367 | $ 2.13 | -0.9 % | $ 4.89 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 28.31 | 0.62 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 106.81 | 0.1 % | $ 8.81 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 260.93 | -4.51 % | $ 21.7 B | USA |
 |
Natera
NTRA
|
9.32 M | $ 193.03 | -4.91 % | $ 19 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 117.14 | -6.02 % | $ 5.48 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 80.59 | -1.03 % | $ 5.44 B | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.68 | 0.15 % | $ 279 M | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 52.63 | 0.23 % | $ 2.67 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 191.51 | -3.19 % | $ 21.3 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.42 | -6.13 % | $ 2.04 B | USA |
 |
ENDRA Life Sciences
NDRA
|
460 K | $ 4.94 | -6.97 % | $ 3.89 M | USA |
 |
Neuronetics
STIM
|
716 K | $ 1.35 | -2.17 % | $ 89 M | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 16.48 | -3.34 % | $ 369 M | USA |